Literature DB >> 9294625

Vascular density is a predictor of cancer-specific survival in prostatic carcinoma.

I F Lissbrant1, P Stattin, J E Damber, A Bergh.   

Abstract

BACKGROUND: Microvessel density has been shown to give prognostic information in a variety of solid tumors, but its role in prostatic carcinoma needs further elucidation.
METHODS: Intratumoral density of von Willebrand factor-positive microvessels was assessed in 98 cases of prostatic carcinoma, diagnosed at transurethral resection of the prostate (TURP) between 1975-1983, using two methods: 1) volume density of microvessels and 2) vascular count in the 2-3 most vascularized fields.
RESULTS: Volume density and vascular counts were highly correlated. In Kaplan-Meyer analysis, mean cancer-specific survival time for patients with a vascular count < 135 was significantly longer than for patients with a vascular count > 135 (P = 0.0064). The same results applied to patients with WHO grade II tumors (P = 0.01). Excluding metastasis in a multivariate analysis, both tumor stage and vascular count had an independent predictive value for cancer-specific survival in patients with WHO grade II tumors.
CONCLUSIONS: Microvessel density may predict cancer-specific survival in prostatic carcinoma.

Entities:  

Mesh:

Year:  1997        PMID: 9294625     DOI: 10.1002/(sici)1097-0045(19970915)33:1<38::aid-pros7>3.0.co;2-5

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

1.  Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-beta activation.

Authors:  Philip P Fitchev; Susan M Wcislak; Chung Lee; Anders Bergh; Charles B Brendler; Veronica M Stellmach; Susan E Crawford; Constantine D Mavroudis; Mona L Cornwell; Jennifer A Doll
Journal:  Lab Invest       Date:  2010-05-10       Impact factor: 5.662

2.  Contrast-enhanced ultrasound imaging of prostate cancer.

Authors:  Ethan J Halpern
Journal:  Rev Urol       Date:  2006

3.  Multi-modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft models.

Authors:  Einar Sulheim; Jana Kim; Annemieke van Wamel; Eugene Kim; Sofie Snipstad; Igor Vidic; Ingeborg Hovde Grimstad; Marius Widerøe; Sverre H Torp; Steinar Lundgren; David J Waxman; Catharina de Lange Davies
Journal:  J Control Release       Date:  2018-04-21       Impact factor: 9.776

Review 4.  Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance.

Authors:  Christine Levesque; Peter S Nelson
Journal:  Cold Spring Harb Perspect Med       Date:  2018-08-01       Impact factor: 6.915

5.  ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors.

Authors:  Heléne Gustavsson; Tajana Tesan; Karin Jennbacken; Kouji Kuno; Jan-Erik Damber; Karin Welén
Journal:  BMC Cancer       Date:  2010-06-14       Impact factor: 4.430

6.  A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer.

Authors:  Srikala S Sridhar; Anthony M Joshua; Richard Gregg; Christopher M Booth; Nevin Murray; Jovana Golubovic; Lisa Wang; Pamela Harris; Kim N Chi
Journal:  Clin Genitourin Cancer       Date:  2014-06-08       Impact factor: 2.872

7.  Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell.

Authors:  Alejandro Godoy; Anica Watts; Paula Sotomayor; Viviana P Montecinos; Wendy J Huss; Sergio A Onate; Gary J Smith
Journal:  Endocrinology       Date:  2008-02-21       Impact factor: 4.736

Review 8.  Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer.

Authors:  William D Figg; Erwin A Kruger; Douglas K Price; Sonia Kim; William D Dahut
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

9.  Identification of EpCAM as a molecular target of prostate cancer stroma.

Authors:  Sumana Mukherjee; Annely M Richardson; Jaime Rodriguez-Canales; Kris Ylaya; Heidi S Erickson; Audrey Player; Ernest S Kawasaki; Peter A Pinto; Peter L Choyke; Maria J Merino; Paul S Albert; Rodrigo F Chuaqui; Michael R Emmert-Buck
Journal:  Am J Pathol       Date:  2009-10-22       Impact factor: 4.307

10.  The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells.

Authors:  M N Thobe; D Gurusamy; P Pathrose; S E Waltz
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.